KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD. – Trademark Portfolio
Entity Type: 99
KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include DIABEGONE. The owner is based in KUNMING CITY, YUNNAN PROVINCE.
6TH FLOOR, NO.166 KEYI ROAD, HIGH TECH
INDUSTRIAL, DEVELOPMENT ZONE
KUNMING CITY, YUNNAN PROVINCE 650106 , CN
Showing of trademarks Trademarks
Trademark Classifications
KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD. have?
KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD. file in?
KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.'s most well-known trademarks?
KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.'s registered trademark portfolio includes well-known marks such as DIABEGONE. These are among 1 currently registered trademark in the portfolio.
What is KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.'s trademark registration success rate?
KUNMING INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.